News Releases

SEATTLE --(BUSINESS WIRE)--Feb. 27, 2019-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced the company will participate in two upcoming

Appoints Immunology Veteran Vijay Kuchroo, DVM, PhD to Scientific Advisory Board SEATTLE --(BUSINESS WIRE)--Feb. 19, 2019-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and

First Dual ICOS/CD28 Inhibitor to Enter Clinical Trials SEATTLE --(BUSINESS WIRE)--Feb. 11, 2019-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today

SEATTLE --(BUSINESS WIRE)--Jan. 16, 2019-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company dedicated to developing innovative treatments for patients suffering from cancer and autoimmune/inflammatory diseases, today announced it has entered into a definitive securities

Company’s Lead Program, ALPN-101, Demonstrates Activity in Animal Models of Graft Versus Host Disease and Hemophagocytic Lymphohistiocytosis Alpine Also Highlights Potential for Transmembrane and Secreted Immunomodulatory Proteins to Enhance Activity of Engineered T Cells Company Adds Distinguished

SEATTLE --(BUSINESS WIRE)--Nov. 29, 2018-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced pre-clinical data from its lead autoimmune/inflammatory

ALPN-202 Preclinical Data Presented at the Society for Immunotherapy of Cancer’s ( SITC ) 33 rd Annual Meeting Supports First-In-Class Triple Mechanism of Action for the Treatment of Cancer Company Strengthens Scientific Advisory Board with Slate of Oncology Leaders SEATTLE --(BUSINESS WIRE)--Nov.

SEATTLE --(BUSINESS WIRE)--Nov. 8, 2018-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing innovative treatments for autoimmune/inflammatory diseases and cancer, today provided a corporate update and reported financial results for the third quarter

SEATTLE --(BUSINESS WIRE)--Nov. 5, 2018-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced the company will participate in two upcoming investor

SEATTLE --(BUSINESS WIRE)--Nov. 1, 2018-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced two upcoming poster presentations at the 60 th American Society